US Patent

US7566462 — Stable tablet formulation

Formulation · Assigned to Biomarin Pharmaceutical Inc · Expires 2025-11-16 · 1y expired

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable solid formulation of tetrahydrobiopterin, specifically sapropterin dihydrochloride, and methods for producing and using it.

USPTO Abstract

The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.

Drugs covered by this patent

sapropterin-dihydrochloride (SAPROPTERIN DIHYDROCHLORIDE)

Patent Metadata

Patent number: US7566462
Jurisdiction: US
Classification: Formulation
Expires: 2025-11-16
Drug substance claim: No
Drug product claim: Yes
Assignee: Biomarin Pharmaceutical Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.